Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
32 participants
INTERVENTIONAL
2019-01-14
2020-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
On admission to the study, all patients will receive on day 1:
Ultrasound measurements of:
Rectus femoris cross-sectional area Thickness of rectus femoris and vastus intermedius Thickness, pennation angle and derived fascicle length of vastus lateralis and medial head of gastrocnemius Thickness of rectus abdominis. Thickness of diaphragm
A blood sample taken from an arterial line A urine sample taken from a urinary catheter A muscle biopsy taken from the right vastus lateralis
They will then receive ten 30 minute sessions of passive cycling with functional electrical stimulation over 14 days, or a control group will receive routine physiotherapy during this period.
Repeat ultrasounds will be taken at days 3, 5, 7, 10 and 14. Repeat blood and urine sampling at days 5, 10 and 14. Repeat muscle biopsy at day 14.
All cycling, ultrasounds and tissue sampling will end on day 14 regardless of the ventilator status of the patient.
In patients who survive to be discharged from critical care, they will be followed up at 3 months for:
Repeat ultrasound scan of all muscles listed Six minute walk test Hand grip and lower limb dynamometry, Balance testing (by standing upright on a pressure plate for 20 seconds) Psychological assessment using the 36 item Short Form (SF-36) questionnaire
Tissue sampling will be stored in the University of Liverpool for analysis of biomarkers of muscle damage and loss between the two groups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Tissue samples will be treated in the same way.
In follow up sessions, participants will be asked not to reveal if they can remember whether they cycled or not.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cycling with FES
Ten sessions of 14 days in patients consented within 48 hours of arriving in critical care who are sedated and mechanically ventilated with a diagnosis of sepsis from any source.
Sessions last a maximum of 30 minutes (with an ideal minimum of 20 minutes), using the Restorative Therapies (RT) 300 Supine with the Sage 12-channel stimulator. Stimulation will provided to the quadriceps, hamstrings, calves and abdomen. Both legs and both sides of the abdomen will be stimulated. Stimulation current settings are individualised for each patient and each muscle group.
These patients will also receive their routine physiotherapy that they would have received if they were in the control group (or not in the trial at all).
Cycling with FES
As described already
Control - routine physiotherapy
Usual daily physiotherapy, consisting of limb care and mobilisation, and respiratory care and exercises as appropriate.
Routine physiotherapy
As described already
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cycling with FES
As described already
Routine physiotherapy
As described already
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Sepsis has been recently redefined as: "Life threatening organ-dysfunction caused by dysregulated host response to infection" whilst septic shock has become a subset of sepsis, defined as: "circulatory and cellular/metabolic dysfunction associated with a higher risk of mortality(44).
For the purposes of this study, a patient will be regarded as septic if they have evidence of infection-related organ failure (e.g. sepsis-associated coagulopathy, altered mental state, cardiovascular dysfunction, acute kidney injury, and altered liver function) and require invasive mechanical ventilation with either definite or suspected evidence of infection. This is to allow prompt treatment with FES rather than waiting for a positive microbiological result to be obtained.
Within the definition of sepsis "from any source" a list of following is illustrative but not exhaustive:
* Urogenital sepsis (including urosepsis, pyelonephritis, endometritis and chorioamnionitis)
* Pneumonia (including community acquired, hospital acquired, and aspiration pneumonia. Ventilator associated pneumonia would be excluded.)
* Neurological infections such as encephalitis and meningitis.
* Cellulitis, osteomyelitis and infections of soft tissue NOT affecting the lower limb.
* Surgical infections, including post-operative laparotomy with evidence of peritoneal soiling, and evidence of infection prior to the operation, in patients who require 2 or more organ system support after the operation.
* Intra-abdominal sepsis, including biliary sepsis, hepatitis, and acute pancreatitis. In the case of acute pancreatitis, evidence of infection is required to fulfil the criteria. Acute pancreatitis with sterile tissue/fluid samples would not be suitable.
Exclusion Criteria
* Patients who decline consent
* Pregnancy
* Neuromuscular disease
* Rhabdomyolysis
* Lower limb trauma
* Patients unlikely to survive to 96 hours post admission
* Consent unobtainable within 48 hours of admission
* Morbid obesity (BMI\>40).
* Presence of a pacemaker or Implantable Cardiac Defibrillator (ICD).
* Unlikely to be mechanically ventilated for more than 48 hours.
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Liverpool
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ingeborg Welters
Senior Lecturer, Institute of Aging and Chronic Disease
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ingeborg D Welters
Role: PRINCIPAL_INVESTIGATOR
University of Liverpool
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Intensive Care Unit, Royal Liverpool University Hospital
Liverpool, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UoL001367
Identifier Type: -
Identifier Source: org_study_id